Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Viltolarsen

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NS Pharma's Duchenne drug Viltepso flunks confirmatory trial
    NS Pharma's Duchenne drug Viltepso flunks confirmatory trial

    29 May 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/ns-pharmas-duchenne-therapy-viltepso-fails-confirmatory-trial

    FIERCE PHARMA
    29 May 2024
    Share Share
    Ns Pharma Viltolarsen Phase 3: Racer53 Preliminary Results Shared
    Ns Pharma Viltolarsen Phase 3: Racer53 Preliminary Results Shared

    27 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ns-pharma-shares-preliminary-results-of-viltolarsen-ns-065--ncnp-01-phase-3-clinical-trial-racer53-study-302155379.html

    PR NEWSWIRE
    27 May 2024
    Share Share
    NS Pharma, Inc. Shares New VILTEPSO® (Viltolarsen) Data at the MDA Conference
    NS Pharma, Inc. Shares New VILTEPSO® (Viltolarsen) Data at the MDA Conference

    06 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ns-pharma-inc-shares-new-viltepso-viltolarsen-data-at-the-mda-clinical--scientific-conference-2024-302080958.html

    PR NEWSWIRE
    06 Mar 2024
    Share Share
    VILTEPSO® (viltolarsen) injection Four-Year Clinical Trial Data Published
    VILTEPSO® (viltolarsen) injection Four-Year Clinical Trial Data Published

    09 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viltepso-viltolarsen-injection-four-year-clinical-trial-data-published-in-the-journal-of-neuromuscular-diseases-301819073.html

    PR NEWSWIRE
    09 May 2023
    Share Share
    VILTEPSO injection Open Label Extension Trial Data Scheduled for Presentation
    VILTEPSO injection Open Label Extension Trial Data Scheduled for Presentation

    19 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viltepso-viltolarsen-injection-open-label-extension-clinical-trial-data-scheduled-for-presentation-at-the-mda-clinical--scientific-conference-2023-301775371.html

    PR NEWSWIRE
    19 Mar 2023
    Share Share
    NS Pharma Reports on Results of VILTEPSO injection
    NS Pharma Reports on Results of VILTEPSO injection

    24 Oct 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/ns-pharma-reports-on-results-of-viltepso-viltolarsen-injection-after-four-years-of-treatment-in-open-label-extension-trial-in-duchenne-muscular-dystrophy-301656722.html

    PRNEWSWIRE
    24 Oct 2022
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.